On-line Supplement

Effects of Sacubitril/valsartan versus Olmesartan on central hemodynamics in the elderly with systolic hypertension: The PARAMETER* Study

Bryan Williams[1], John R Cockcroft[2], Kazuomi Kario[3], Dion H Zappe[4], Patrick C Brunel[5], Qian Wang[4], Weinong Guo[6]

Affiliations:

[1]Department of Cardiovascular Sciences, University College London (UCL), London and National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK;

[2]Department of Cardiology, University of Cardiff, Wales, UK;

[3]Jichi Medical School, Tochigi, Japan;

[4]Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

[5]Novartis Pharma AG, Basel, Switzerland

[6]Beijing Novartis Pharma Co. Ltd. Shanghai, China

*PARAMETER, Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly study

*PARAMETER, Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly study

Appendix 1

Participating study sites and investigators

Prinicipal Investigator	**Participating Center**
Claudio Majul	CENUDIAB, Buenos Aires, Buenos Aires, C1440AAD
Oscar Montana	DIM Clinica Privada, Buenos Aires, Buenos Aires, B1704ETD
Daniel Piskorz	Sanatorio Britanico, Rosario, Santa Fe, S2000CXH
Miguel Urina Triana	Fundacion BIOS, Barranquilla, Atlantico
Alberto Cadena	Clínica de La Costa, Barranquilla
Roland Schmieder	CRC Clin.Research Center, Nuernberg, 90471
Juergen Scholze	Med. Poliklinik der Humboldt-Univ./Campus Charité Mitte, Berlin, 10117
Laia Sans Atxer	Hospital del Mar, Barcelona, Cataluña, 08003
Josefina Olivan Martinez	Hospital Universitario Virgen Macarena, Sevilla, Andalucia, 41071
Carlos Calvo	Hospital Clinico Universitario Santiago De Compostela, La Coruña, Galicia, 15706
Jose Pascual	Hospital De Sagunto, Puerto de Sagunto, Comunidad Valenciana, 46520
Pablo Gomez	Hospital General De Jerez De La Frontera, Jerez de La Frontera,

	Andalucia, 11407
Julian Segura	Hospital 12 de Octubre, Madrid, 28041
Luis Ruilope	Hospital 12 de Octubre, Madrid, Madrid, 28041
Jose Luis Zamorano Gomez	Hospital Ramon Y Cajal, Madrid, Madrid, 28034
Alejandro de la Sierra	Hospital Mutua de Terrassa, Terrassa, Cataluña, 08221
Silvia Narejos Pérez	Centre d'Atenció Primaria Centelles, Centelles, Centelles, Cataluña, 08540
Patricia Fernández Llama	Fundacion Puigvert, Barcelona Catalunya 08025
Gilles Chironi	Hopital Europeen Georges Pompidou, Paris, France, 75015
Konstantinos Tsioufis	Ippokrateio General Hospital of Athens, Athens, 11525
Anastasios Spanos	Athens Naval Hospital, Athens, Athens, 11526
Michalis Doumas	Ippokrateio General Hospital of Thessaloniki, Thessaloniki, Thessaloniki, 54642
Stefano Taddei	A.O.Univ.Pisana-Pres.Osp.S.Chiara-Univ.degli Studi, Pisa, PI, 56126
Maurizio Destro	Pres.Osped.di Treviglio-Az.Osped.di Treviglio-Caravaggio, Treviglio,BG, 24047
Lucio Mos	P.O.Ospedale Civile S.Antonio ASS 4 Medio Friuli, San Daniele Del Friuli, UD, 33038
Satoshi Hoshide	Jichi Medical University Hospital, Shimotsuke-city, Tochigi, 329-0498

Haeyoung Lee	Seoul National University Hospital, Seoul, Korea, 110 744
Sanghyun Ihm	The Catholic University of Korea, Bucheon St.Mary Hospital, Bucheon, Gyeonggi-do, 424-717
Zhanna Kobalava	Russian University of People Friendship, Moscow, 117292
Sergey Martsevich	State Research Centre for Preventive Medicine, Moscow, 101990
Ludmila Pavlova	Moscow Medical Academy n.a. Sechenov, Moscow, 119992
Elena Baranova	State Pavlov Medical University, Saint-Petersburg, 197022
Alexandra Konradi	Federal North-West Medical Research Centre, Saint- Petersburg, 197341
Tatiana Treshkur	Federal North-West Medical Research Centre,, Saint- Petersburg, 197341
Maria Mozheiko	Yaroslavl Regional Hospital of Veterans of Wars, Yaroslavl, 150047
Kuan-Cheng Chang	China Medical University Hospital (Taichung), Taichung, 4044
Chen-Huan Chen	Taipei Veterans General Hospital, Taipei, Taiwan, 112
Bing-Hsiean Tzeng	Tri-Service General Hospital, Taipei, Taiwan, 114
Harvey Resnick	R/D Clinical Research, Inc., Lake Jackson, TX, 77566
Gordon Sack	Med-Olam Clinical Research, Pasadena, TX, 77504
Timothy Smith	Mercy Health Research, St. Louis, MO, 63141
Miguel Trevino	Innovative Research of West Florida, Clearwater, FL, 33756
Andrea Phillips	Phillips Medical Center, Jackson, MS, 39209
Danny Sugimoto	Cedar Crosse Research Center, Chicago, IL, 60607

James Fidelholtz	High Top Medical Research Center, Cincinnati, OH, 45224
Sidney Gorton	Belzoni Clinical Research, Belzoni, MS, 39038
Vicki E. Miller	Texas Center for Drug Development, P.A., Houston, TX, 77081
James Mersey	Model Clinical Research, Baltimore, MD, 21204
Veronica Garcia-Fragoso	Texas Center for Drug Development, P.A. Houston TX 77081
Abdulla Salahudeen	Texas Center for Drug Development, P.A. Houston TX 77081
Joseph L. Izzo	Erie County Medical Center - Dept. of Cardiology, Buffalo, NY, 14215

Supplementary figures

Online Supplement Figure S1. Parameter study design



*Patients initially randomized to LCZ696 200 mg qd or olmesartan 20 mg qd, followed by forced-titration at Week 4 to double the initial dose, which was continued throughout the study. Hemodynamic measurements (seated clinic and 24hr ambulatory brachial BP, central aortic pressures and pulse wave velocity) were recorded at baseline, 12 weeks and 52 weeks.

Online Supplement Figure S2. Geometric mean change from baseline in (A) plasma NT-proBNP and (B) urine cGMP/creatinine ratio at Week 12 endpoint and Week 52 endpoint



Data are percentage change in geometric change (95% confidence intervals)
NT-proBNP, N-terminal pro brain natriuretic peptide; cGMP, cyclic guanosine monophosphate

Online Supplement Figure S3.
Post hoc analysis. Changes in PWV changes at Week 12 and Week 52 endpoints (A); Upper quartile changes in PWV (B), CASP (C) and brachial SBP (D) at Week 12 and 52 endpoints



Between-treatment comparisons utilize paired analysis of patients who had a valid PWV at baseline and at week 52; analysis of covariance model included treatment, region, baseline PWV as predictors
PWV, pulse wave velocity; SBP, systolic blood pressure

Online Supplement Figure S4.
Change in carotid-femoral PWV with treatment from baseline to 12 weeks (A) and 52 weeks (B), stratified by quartiles of baseline PWV.



Online Supplement Figure S5.

Change in brachial systolic blood pressure (SBP) mmHg and pulse pressure (PP) mmHg from baseline to 12 weeks.